Fundraising Fox
Avalyn Pharma Inc
NASDAQ: AVLN63 employees on LinkedIn · 21 known investors
Find your way into Avalyn Pharma Inc
Sign up to see every warm intro you have to Avalyn Pharma Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avalyn Pharma Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
Founders & leadership
Investors · 21
How we know: Andera Partners's portfolio page · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · globenewswire.com · Not right? Tell us
How we know: InVivium Capital's portfolio page · Not right? Tell us
How we know: globenewswire.com · Not right? Tell us
How we know: Pivotal Life Sciences's portfolio page · globenewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · globenewswire.com · Not right? Tell us
How we know: SR One Capital Management's portfolio page · the S-1 prospectus · a partner's Signal profile · Not right? Tell us
How we know: Vida Ventures's portfolio page · the S-1 prospectus · globenewswire.com · the VCSheet dataset · Not right? Tell us
How we know: globenewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
.jpeg){kind=logo}
How we know: a partner's Signal profile · Not right? Tell us
How we know: the S-1 prospectus · globenewswire.com · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$445.4M disclosed across 2 of 6 rounds · 1900–2026
- $345MIPOMay 2026 · 3 sourcesSource ↗
- Undisclosed amountSeries CSep 2023
Eventide Asset Management (lead), Perceptive Xontogeny Venture Funds (lead), SR One (lead), Catalio Capital Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings A/S, Piper Heartland, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, Surveyor Capital (a Citadel Company), T. Rowe Price Associates, Inc., Vida Ventures, Wellington Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
Companies working in the same space as Avalyn Pharma Inc.
In the news
Frequently asked questions
- What does Avalyn Pharma Inc do?
- Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
- Who are Avalyn Pharma Inc's investors?
- Avalyn Pharma Inc's investors include Andera Partners, Catalio Capital Management, LP, F-Prime Capital, InVivium Capital, Norwest Venture Partners, Pivotal Life Sciences, RiverVest Venture Partners, SR One Capital Management and 8 more.
- How much funding has Avalyn Pharma Inc raised?
- Avalyn Pharma Inc has disclosed $445.4M raised across 2 of its 6 known rounds.